Farmer, C., Thurm, A., & Grant, P. (2013). Pharmacotherapy for the core symptoms in autistic disorder: Current status of the research. Drugs, 73(4), 303-314. doi: 10.1007/s40265-013-0021-7.
Handen, B.L., Johnson, C.R., McAuliffe-Bellin, S., Murray, P.J., & Hardan, A.Y. (2011). Safety and efficacy of donepezil in children and adolescents with autism: Neuropsychological measures. Journal of Child and Adolescent Psychopharmacology, 21(1), 43-50. doi: 10.1089/cap.2010.0024.
King, B.H., & Bostic, J.Q. (2006). An update on pharmacologic treatments for autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America, 15(1), 161-175. doi: 10.1016/j.chc.2005.08.005.
Lippiello, P.M. (2006). Nicotinic cholinergic antagonists: A novel approach for the treatment of autism. Medical Hypotheses, 66, 985-990. doi: 10.1016/j.mehy.2005.11.015.
National Autism Center (2015). Findings and conclusions: National standards project, phase 2. Randolph, MA: National Autism Center. Retrieved 26 September 2016 from http://www.nationalautismcenter.org/national-standards-project/results-reports/.
Picciotto, M.R., Higley, M.J., & Mineur, Y.S. (2012). Acetylcholine as a neuromodulator: Cholinergic signaling shapes nervous system function and behavior. Neuron, 76(1), 116-129. doi: 10.1016/j.neuron.2012.08.036.
Prior, M., & Roberts, J. (2012). Early intervention for children with autism spectrum disorders: Guidelines for good practice. Canberra: Australian Government Department of Social Services. Retrieved 23 June 2016 from https://www.dss.gov.au/our-responsibilities/disability-and-carers/program-services/for-people-with-disability/early-intervention-for-children-with-autism-spectrum-disorders-guidelines-for-good-practice-2012.
Prior, M., Roberts, J.M., Rodger, S., Williams, K., & Sutherland, R. (2011). A review of the research to identify the most effective models of practice in early intervention for children with autism spectrum disorders. Canberra: Australian Government Department of Families, Housing, Community Services and Indigenous Affairs. Retrieved 26 September 2016 from https://www.dss.gov.au/sites/default/files/documents/10_2014/review_of_the_research_report_2011_0.pdf.
Rossignol, D.A., & Frye, R.E. (2014). The use of medications approved for Alzheimer’s disease in autism spectrum disorder: A systematic review. Frontiers in Pediatrics, 2(87), 1-8. doi: 10.3389/fped.2014.00087.
Weitlauf, A.S., McPheeters, M.L., Peters, B., Sathe, N., Travis, R., Aiello, R., Williamson, E., Veenstra-VanderWeele, J., Krishnaswami, S., Jerome, R., & Warren, Z. (2014). Therapies for children with autism spectrum disorder: Behavioral interventions update. Comparative Effectiveness Review no. 137 [AHRQ Publication No. 14-EHC036-EF]. Rockville, MD: Agency for Healthcare Research and Quality. Retrieved 25 July 2016 from http://www.ncbi.nlm.nih.gov/books/NBK241444/.
Wong, C., Odom, S.L., Hume, K., Cox, A.W., Fettig, A., Kucharczyk, S., Brock, M.E., Plavnick, J.B., Fleury, V.P., & Schultz, T.R. (2014). Evidence-based practices for children, youth, and young adults with autism spectrum disorder. Chapel Hill, NC: University of North Carolina, Frank Porter Graham Child Development Institute, Autism Evidence-Based Practice Review Group. Retrieved 25 July 2016 from http://fpg.unc.edu/sites/fpg.unc.edu/files/resources/reports-and-policy-briefs/2014-EBP-Report.pdf.